Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer

NCT03937141 is registered in ClinicalTrials.gov with Chinook Therapeutics, Inc. (formerly Aduro) as lead sponsor.

NCT NCT03937141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03937141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Lead sponsor
Chinook Therapeutics, Inc. (formerly Aduro)
Phase
Phase 2
Overall status
Terminated
Start date
August 26, 2019
Completion date
June 10, 2021
Enrollment
16 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic head and neck cancer, recurrent head and neck cancer